False-negative fluorine-18-FDG PET in metastatic carcinoid.
Carcinoid tumors have high numbers of somatostatin receptors that allow scintigraphic imaging with the radiolabeled somatostatin analog octreotide. Experience, however, with PET using 2-[18F]fluoro-2-deoxy-D-glucose (18FDG) in carcinoid is very limited. In two prior studies which investigated the utility of 18FDG-PET in cancer detection, three patients with small, solitary, indolent carcinoid tumors had false-negative results. We report a case where 18FDG-PET imaging was false-negative in a patient with known metastatic carcinoid and a positive octreotide scan.
Jadvar
H
H
Nuclear Medicine Service, VA Palo Alto Health Care System, California 94304, USA.
Segall
G M
GM
D002276:Carcinoid Tumor / Q000150:complications / Q000000981:diagnostic imaging* / Q000556:secondary*; D003847:Deoxyglucose / Q000031:analogs & derivatives*; D005188:False Negative Reactions; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006679:HIV Seropositivity / Q000150:complications*; D006801:Humans; D007078:Ileal Neoplasms / Q000150:complications / Q000000981:diagnostic imaging; D008113:Liver Neoplasms / Q000150:complications / Q000000981:diagnostic imaging* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D019275:Radiopharmaceuticals; D014055:Tomography, Emission-Computed
D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose